Vinay Prasad departs FDA | STAT
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middle
Jennifer Hill Blair recognized the Cincinnati number on her buzzing phone and slipped out of the school meeting,…
Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA rejects Replimune skin cancer therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA rejects Capricor’s Duchenne cell therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…